Pharmacokinetics of Voriconazole in Obese Subjects

Phase 4 Completed 10 enrolled Manjunath Prakash Pai Pfizer · collab TKL Research, Inc. · collab

RandomizedCrossoverOpen-labelHealth-services research

Summary

Obese subjects may require a higher fixed oral maintenance dosing regimen of voriconazole compared to normal weight subjects to achieve comparable plasma exposures. The current study is designed to address this issue.

Timeline

Start: 2009-11
Primary completion: 2010-04
Completion: 2010-05

Publications

Background Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7. doi: 10.1128/AAC.00059-07. Epub 2007 Jun 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Voriconazole	Small molecule	200 mg	Oral
Subject	Voriconazole	Small molecule	300 mg	Oral

Indications

No indication recorded.